Loxagen

Loxagen is a biotechnology company focused on developing neuroprotective therapies for stroke and other neurodegenerative diseases. The company's lead candidate, BPN-27332, is a highly selective small molecule inhibitor of the 12/15-lipoxygenase (ALOX15) enzyme, which is a key driver of neuronal death and blood-brain barrier breakdown following brain injury. Loxagen's research, supported by over $10 million in funding and the NIH Blueprint Neurotherapeutics Program, aims to address the significant unmet need in subarachnoid hemorrhage (SAH) and ischemic stroke. The company is currently evaluating its lead compound in the Stroke Preclinical Assessment Network (SPAN) to prepare for future clinical trials.